Boyarsky BJ, Po‐Yu Chiang T, Werbel WA, et al. Early impact of COVID‐19 on transplant center practices and policies in the United States. Am J Transplant. 2020;00:1--10. 10.1111/ajt.15915

ACEi

:   angiotensin‐converting enzyme inhibitor

ARB

:   angiotensin receptor blocker

BAL

:   bronchoalveolar lavage

CDC

:   centers for disease control

CNI

:   calcineurin inhibitor

COVID‐19

:   coronavirus disease 2019

DDKT

:   deceased donor kidney transplantation

DDLT

:   deceased donor liver transplantation

ECMO

:   extracorporeal membranous oxygenation

HCQ

:   hydroxychloroquine

IS

:   immunosuppression

LAS

:   lung allocation score

LDKT

:   live donor kidney transplantation

LDLT

:   live donor liver transplantation

NAT

:   nucleic acid test

NP

:   nasopharyngeal

PMP

:   per million population

PPE

:   personal protective equipment

RSV

:   respiratory syncytial virus

RVP

:   respiratory viral panel

SARS‐CoV‐2

:   severe acute respiratory syndrome coronavirus 2

SOT

:   solid organ transplant

WHO

:   World Health Organization

1. INTRODUCTION {#ajt15915-sec-0001}
===============

COVID‐19 has quickly and dramatically impacted the world.[^1^](#ajt15915-bib-0001){ref-type="ref"}, [^2^](#ajt15915-bib-0002){ref-type="ref"}, [^3^](#ajt15915-bib-0003){ref-type="ref"}, [^4^](#ajt15915-bib-0004){ref-type="ref"}, [^5^](#ajt15915-bib-0005){ref-type="ref"} Given the early nature of the pandemic, knowledge about COVID‐19 and its impact on solid organ transplantation (SOT) patients is limited to case reports and expert discussion.[^6^](#ajt15915-bib-0006){ref-type="ref"}, [^7^](#ajt15915-bib-0007){ref-type="ref"}, [^8^](#ajt15915-bib-0008){ref-type="ref"} There is insufficient knowledge about the natural history of COVID‐19,[^9^](#ajt15915-bib-0009){ref-type="ref"}, [^10^](#ajt15915-bib-0010){ref-type="ref"} including lack of understanding about the potential for donor‐derived infection given imperfections in currently available diagnostic tests.[^2^](#ajt15915-bib-0002){ref-type="ref"}, [^11^](#ajt15915-bib-0011){ref-type="ref"} There is ongoing nosocomial and community spread,[^12^](#ajt15915-bib-0012){ref-type="ref"} and more severe illness has been observed for patients with underlying conditions.[^3^](#ajt15915-bib-0003){ref-type="ref"}, [^13^](#ajt15915-bib-0013){ref-type="ref"}, [^14^](#ajt15915-bib-0014){ref-type="ref"}, [^15^](#ajt15915-bib-0015){ref-type="ref"}, [^16^](#ajt15915-bib-0016){ref-type="ref"}, [^17^](#ajt15915-bib-0017){ref-type="ref"} Previous experience with related viruses, SARS‐CoV in 2003,[^18^](#ajt15915-bib-0018){ref-type="ref"} and MERS‐CoV in 2015,[^19^](#ajt15915-bib-0019){ref-type="ref"} demonstrated that SOT recipients may be anticipated to have prolonged viral shedding, potentially increasing transmissibility, morbidity, and mortality.[^6^](#ajt15915-bib-0006){ref-type="ref"}, [^20^](#ajt15915-bib-0020){ref-type="ref"}

There are several ways transplant centers can approach the COVID‐19 pandemic to mitigate risk for SOT candidates and recipients. Specifically, centers can restrict access to transplantation based on urgency and limit use of donors based on exposure risk. Transplant centers can modify evaluation and monitoring practices of non--COVID‐19‐SOT patients, develop screening and testing algorithms for suspected cases and treatment protocols for confirmed cases. Furthermore, centers can risk‐stratify COVID‐19--SOT patients based on disease severity to help allocate appropriate resources to the sickest and most vulnerable patients. However, there are currently no evidence based‐guidelines to inform these practices.

To better understand the early impact of COVID‐19 on transplant activity across the United States, and to explore center‐level variation in testing, clinical practice, and policies, we conducted a national survey of US transplant centers between March 24, 2020 and March 31, 2020. We gathered data in 4 domains: (a) current transplant activity, (b) COVID‐19 impact on practices, (c) testing algorithms, and (d) treatment practices. We purposefully conducted our survey at a relatively early stage of US COVID‐19 activity in the hopes that rapid dissemination of center‐level practices, policies, and perceptions could inform decision‐making in other centers in the United States and around the world.

2. METHODS {#ajt15915-sec-0002}
==========

2.1. Study population {#ajt15915-sec-0003}
---------------------

We studied transplant centers in the United States with an annual volume of ≥100 transplants per year (calculated by the average total number of SOTs in 2018 and 2019). These 111 centers perform 87.6% of the adult transplant volume in the United States.

2.2. Survey design {#ajt15915-sec-0004}
------------------

The survey instrument was developed using an iterative process, based on a thorough review of the literature surrounding COVID‐19,[^21^](#ajt15915-bib-0021){ref-type="ref"}, [^22^](#ajt15915-bib-0022){ref-type="ref"}, [^23^](#ajt15915-bib-0023){ref-type="ref"}, [^24^](#ajt15915-bib-0024){ref-type="ref"}, [^25^](#ajt15915-bib-0025){ref-type="ref"} and discussions with transplant surgeons and transplant ID physicians. The final survey was approved by two transplant surgeons and two transplant ID physicians with input from members of the transplant team ([Supplement](#ajt15915-sup-0001){ref-type="supplementary-material"}).

2.3. Survey conduct {#ajt15915-sec-0005}
-------------------

The survey was conducted between March 24, 2020 and March 31, 2020. At each center, we identified one clinical transplant leader who we anticipated would have knowledge about their center\'s COVID‐19 practices and policies. Participants were e‐mailed links to the survey, and encouraged to either fill out the survey themselves if they felt comfortable, gather data from among colleagues and provide a center‐wide response, or pass the survey along to someone who they felt was more appropriate to answer the questions. The online survey was hosted by Qualtrics. Respondents were not compensated.

2.4. Survey domains {#ajt15915-sec-0006}
-------------------

We asked questions in 4 domains: (a) current transplant activity, (b) COVID‐19 impact on practices, (c) testing algorithms, and (d) treatment practices. For each domain, we asked practice and perception questions. For domain (a), we asked current level of transplant activity (no restrictions, minor restrictions, major restrictions, suspension), and perceptions on what transplant activities should continue. For domain (b), we asked about overall level of concern about risk of COVID‐19 for SOT recipients (extremely concerned, highly concerned, neutral, somewhat concerned, not concerned) and perception of shortages of critical supplies, equipment and care areas (anticipated or current). We also asked about changes in outpatient monitoring of SOT recipients. For domain (c), we asked about COVID‐19 testing availability. We asked about ease of testing within several time periods (extremely easy, easy, neutral, difficult, extremely difficult), and testing algorithms for recipients and donors. For domain (d), we asked numbers of cases of COVID‐19 by organ and perceived severity of illness (mild/no pneumonia, moderate/pneumonia, critically ill), as well as time since transplant (in years). We investigated pharmacologic therapies used by respondents, and changes in immunosuppressive regimens for COVID‐19--SOT patients.

2.5. Cumulative incidence by geographic area {#ajt15915-sec-0007}
--------------------------------------------

Using data from the Johns Hopkins COVID‐19 incidence map and the CDC, we linked the cumulative incidence of COVID‐19 in each state on March 24 (the day the survey was administered) to each respondent\'s survey answers.[^26^](#ajt15915-bib-0026){ref-type="ref"}, [^27^](#ajt15915-bib-0027){ref-type="ref"} We divided the total number of cases in each state by state population (from the US Census) to derive cumulative incidence per million population (PMP).[^28^](#ajt15915-bib-0028){ref-type="ref"} Twenty‐two centers in 8 states whose COVID‐19 cumulative incidence were above national average (163 PMP) were defined as centers in high‐impact areas.

2.6. Statistical analysis {#ajt15915-sec-0008}
-------------------------

For statistical purposes, each question was treated as a complete case analysis. We tested the association between transplant activity and level of COVID‐19 impact by Fischer\'s exact test and reported significance level using *P* \< .05. All analyses were performed using Stata 16.0/MP for Linux.

3. RESULTS {#ajt15915-sec-0009}
==========

3.1. Study population {#ajt15915-sec-0010}
---------------------

Among the 111 transplant centers surveyed, 88 responded (79.3%) (Table [1](#ajt15915-tbl-0001){ref-type="table"}). The majority of respondents, 53/88 (60.2%), were transplant surgeons, and 22/88 (25.0%) were transplant infectious diseases (ID) physicians; 82/86 (95.3%) reported expertise in DDKT, and 63/86 (73.3%) in DDLT; 71/88 (80.7%) were academic centers, and 22/88 (25.0%) came from areas of high COVID‐19 cumulative incidence.

###### 

Characteristics of survey respondents and transplant centers

+-----------------------------------------------------------------------------+-----------+
|                                                                             | n = 88    |
|                                                                             |           |
|                                                                             | n (%)     |
+=============================================================================+===========+
| Transplant role                                                             |           |
+-----------------------------------------------------------------------------+-----------+
| Surgeon                                                                     | 53 (60.2) |
+-----------------------------------------------------------------------------+-----------+
| Infectious diseases                                                         | 22 (25.0) |
+-----------------------------------------------------------------------------+-----------+
| Nephrologist                                                                | 8 (9.2)   |
+-----------------------------------------------------------------------------+-----------+
| Hepatologist                                                                | 1 (1.1)   |
+-----------------------------------------------------------------------------+-----------+
| Administrator                                                               | 4 (4.6)   |
+-----------------------------------------------------------------------------+-----------+
| Expertise with center‐level policy[^b^](#ajt15915-note-0003){ref-type="fn"} |           |
+-----------------------------------------------------------------------------+-----------+
| Live donor KT                                                               | 80 (93.0) |
+-----------------------------------------------------------------------------+-----------+
| Deceased donor KT                                                           | 82 (95.3) |
+-----------------------------------------------------------------------------+-----------+
| Live donor LT                                                               | 34 (39.5) |
+-----------------------------------------------------------------------------+-----------+
| Deceased donor LT                                                           | 63 (73.3) |
+-----------------------------------------------------------------------------+-----------+
| Pancreas                                                                    | 58 (67.4) |
+-----------------------------------------------------------------------------+-----------+
| Heart                                                                       | 33 (38.4) |
+-----------------------------------------------------------------------------+-----------+
| Lung                                                                        | 28 (32.6) |
+-----------------------------------------------------------------------------+-----------+
| Center designation                                                          |           |
+-----------------------------------------------------------------------------+-----------+
| Academic                                                                    | 71 (80.7) |
+-----------------------------------------------------------------------------+-----------+
| Community                                                                   | 17 (19.3) |
+-----------------------------------------------------------------------------+-----------+
| COVID‐19 prevalence                                                         |           |
+-----------------------------------------------------------------------------+-----------+
| High‐impact[^a^](#ajt15915-note-0002){ref-type="fn"}                        | 22 (25.0) |
+-----------------------------------------------------------------------------+-----------+
| COVID‐19 testing availability[^c^](#ajt15915-note-0004){ref-type="fn"}      |           |
+-----------------------------------------------------------------------------+-----------+
| Nasopharyngeal NAT                                                          | 81 (98.8) |
+-----------------------------------------------------------------------------+-----------+
| Bronchoalveolar lavage NAT                                                  | 57 (69.5) |
+-----------------------------------------------------------------------------+-----------+
| Blood NAT                                                                   | 14 (17.1) |
+-----------------------------------------------------------------------------+-----------+

State cumulative incidence greater than national average (\>163 per‐million‐population) on March 24, 2020.

n = 86.

n = 82 could choose more than one option.
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3.2. Current transplant activity {#ajt15915-sec-0011}
--------------------------------

### 3.2.1. Practices {#ajt15915-sec-0012}

Among LDKT programs, 56/78 (71.8%) reported full suspension of transplantation (Figure [1A](#ajt15915-fig-0001){ref-type="fig"}). Operational restrictions (some or major) were reported in 19/78 (24.4%) of LDKT programs. Among DDKT programs, 65/81 (80.2%) were operating with some or major restrictions. Among LDLT programs, 21/31 (67.7%) were suspended. LDLT programs were more likely to be suspended in higher impact areas (*P* = .03). Among DDLT programs, 16/60 (26.7%) were operating without restriction. Pancreas transplantation was suspended at 22/56 (39.3%). Among heart programs, 6/32 (18.8%) were continuing without restriction. For lung programs, 5/27 (18.5%) were operating without restriction.

![A, Transplant center SOT activity by state‐level cumulative incidence of COVID‐19. B, Perceptions of SOT activity that should continue by organ and state‐level cumulative incidence of COVID‐19. Cumulative incidence PMP on March 24, 2020](AJT-9999-na-g001){#ajt15915-fig-0001}

Examples of LDKT restrictions included: transplanting only preemptive KTs, well‐recipients, and those with lack of dialysis access. Some restrictions were driven by limited operating room (OR) staffing. Common DDKT restrictions included: transplanting only highly sensitized patients, those with negative cross‐match, higher acuity patients, and those without dialysis access. Others reported transplanting only healthier recipients with the best quality organs and lowest risk of delayed graft function (DGF). Among those LDLT operating with restrictions, respondents noted transplanting patients only with high probability of mortality in 1‐3 months; others reported that the LDLT evaluation process has stopped or slowed down. Common restrictions on DDLT included: transplanting higher acuity (MELD \> 25 or acute liver failure) patients, inpatients only, those who were not anticipated to require blood products intraoperatively, first‐time transplants, and those with tumors without other options. Some respondents reported being limited by supplies and capacity. Reasons for suspension of pancreas transplantation included: avoiding occupying ICU beds, and because of risk of prolonged hospitalization with increased risk of readmission. Some heart programs were restricting to the most severe cases (status 1‐3, inpatients). Some lung programs were restricting by lung allocation score (LAS) \>45, though some reported inactivating the majority of patients.

### 3.2.2. Perceptions {#ajt15915-sec-0013}

Regarding respondents' perceptions about continuation of transplant practices, 54/85 (63.5%) of respondents thought LDKT should be suspended; 10/85 (11.8%) DDKT; 38/73 (52.1%) LDLT; 4/79 (5.1%) DDLT; 36/75 (48.0%) pancreas; 2/60 (3.3%) heart; and 5/58 (8.6%) lung (Figure [1B](#ajt15915-fig-0001){ref-type="fig"}).

3.3. COVID‐19 impact and transplant center needs {#ajt15915-sec-0014}
------------------------------------------------

### 3.3.1. Practices {#ajt15915-sec-0015}

In‐person outpatient visits for SOT recipients were reported to be limited by 62/63 (98.4%) of respondents; 13/63 (20.6%) of respondents reported stopping or limiting lab draws at the hospital; and 61/63 (96.8%) reported using telemedicine (Table [2](#ajt15915-tbl-0002){ref-type="table"}). For KT recipients, 53/77 (68.8%) respondents reported developing COVID‐19 testing protocols; 43/62 (69.4%) for LT; 28/55 (50.9%) for pancreas; 25/46 (54.4%) for heart, and 24/37 (64.9%) for lung. Fewer respondents reported developing treatment protocols: 46/77 (59.7%) for KT; 34/62 (54.8%) for LT; 30/55 (54.6%) for pancreas recipients; 23/46 (50.0%) for heart recipients; and 18/37 (48.7%) for lung recipients. Donor testing protocols were developed for 67/77 (87.0%) for KT; 53/62 (85.5%) for LT; 47/55 (85.5%) for pancreas; 40/46 (86.9%) for heart; and 31/37 (83.8%) for lung.

###### 

Respondents who reported changes in outpatient practices and developed COVID‐19 recipient/donor testing and treatment protocols

+--------------------------+-----------+
| Changes in OP monitoring | n = 63    |
|                          |           |
|                          | n (%)     |
+==========================+===========+
| Stopped visits           | 5 (7.9)   |
+--------------------------+-----------+
| Limited visits           | 62 (98.4) |
+--------------------------+-----------+
| Limited laboratory draws | 13 (20.6) |
+--------------------------+-----------+
| Telemedicine             | 61 (96.8) |
+--------------------------+-----------+

+------------------------+--------------+-------------+----------------+-------------+------------+
|                        | Kidney n (%) | Liver n (%) | Pancreas n (%) | Heart n (%) | Lung n (%) |
|                        |              |             |                |             |            |
|                        | n = 77       | n = 62      | n = 55         | n = 46      | n = 37     |
+========================+==============+=============+================+=============+============+
| SOT testing protocol   | 53 (68.8)    | 43 (69.4)   | 28 (50.9)      | 25 (54.4)   | 24 (64.9)  |
+------------------------+--------------+-------------+----------------+-------------+------------+
| SOT treatment protocol | 46 (59.7)    | 34 (54.8)   | 30 (54.6)      | 23 (50.0)   | 18 (48.7)  |
+------------------------+--------------+-------------+----------------+-------------+------------+
| Donor testing protocol | 67 (87.0)    | 53 (85.4)   | 47 (85.5)      | 40 (87.0)   | 31 (83.8)  |
+------------------------+--------------+-------------+----------------+-------------+------------+

Respondents could choose more than one option.
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### 3.3.2. Perceptions {#ajt15915-sec-0016}

Regarding level of concern about COVID‐19 risk for current SOT recipients, 74/87 (85.1%) reported feeling extremely or highly concerned (Figure [2](#ajt15915-fig-0002){ref-type="fig"}), which did not change based on state‐level cumulative incidence of COVID‐19 (*P* = .8). Regarding COVID‐19 testing supplies, 31/73 (42.5%) respondents reported current shortage of COVID‐19 tests, and an additional 17/73 (23.3%) anticipated shortage of tests (Figure [3](#ajt15915-fig-0003){ref-type="fig"}). Regarding perceptions of shortages of critical supplies, equipment and capacity to care for critically ill patients, 53/75 (70.7%) reported anticipated shortage of personal protective equipment (PPE); 56/73 (76.7%) intensive care unit (ICU) beds; 49/70 (70.0%) ventilators and negative pressure rooms; 51/71 (71.8%) blood products; and 37/64 (57.8%) anticipated shortage of extracorporeal membranous oxygenation (ECMO). These differences in availability of critical supplies were not statistically significantly different by level of COVID‐19 impact.

![Distribution of respondent concern by state‐level cumulative incidence. Cumulative incidence PMP on March 24, 2020](AJT-9999-na-g002){#ajt15915-fig-0002}

![Respondent perception of anticipated and current shortages of supplies by state‐level cumulative incidence. Cumulative incidence PMP on March 24, 2020](AJT-9999-na-g003){#ajt15915-fig-0003}

3.4. COVID‐19--SOT patient testing {#ajt15915-sec-0017}
----------------------------------

### 3.4.1. Practices {#ajt15915-sec-0018}

Nasopharyngeal (NP) nucleic acid test (NAT) for COVID‐19 was available for 81/82 (98.8%) of respondents; bronchoalveolar lavage (BAL) NAT was available for 57/82 (69.5%); and blood NAT for 14/82 (17.1%) (Table [1](#ajt15915-tbl-0001){ref-type="table"}).

Regarding testing practices, the most common test for suspected cases of COVID‐19 in SOT recipients was simultaneous full respiratory viral panel (RVP) with COVID‐19, 35/74 (47.3%) (Table [3](#ajt15915-tbl-0003){ref-type="table"}). Other common algorithms were isolated COVID‐19 testing 21/74 (28.4%); and reflex COVID‐19 testing if influenza, respiratory syncytial virus (RSV), or full RVP were negative.

###### 

Testing algorithm for suspected COVID‐19--SOT recipients and potential deceased donors

  Algorithm[^c^](#ajt15915-note-0009){ref-type="fn"}                                   n (%)
  ------------------------------------------------------------------------------------ -----------
  Reflex COVID‐19 if Influenza/RSV[^a^](#ajt15915-note-0007){ref-type="fn"} negative   13 (17.6)
  Reflex COVID‐19 if full RVP[^b^](#ajt15915-note-0008){ref-type="fn"} negative        8 (10.8)
  Simultaneous full RVP, COVID‐19                                                      35 (47.3)
  Up‐front COVID‐19                                                                    21 (28.4)

  Proposed deceased donor testing   Low‐risk[^d^](#ajt15915-note-0010){ref-type="fn"}   High‐risk[^e^](#ajt15915-note-0011){ref-type="fn"}
  --------------------------------- --------------------------------------------------- ----------------------------------------------------
  Nasopharyngeal NAT                57 (73.1)                                           51 (63.8)
  Bronchoalveolar lavage NAT        20 (25.6)                                           44 (55.0)
  Blood NAT                         9 (11.3)                                            19 (23.8)
  No NAT                            2 (2.5)                                             1 (1.3)

Respondents could choose more than one algorithm or test.

Respiratory syncytial virus.

Respiratory viral panel.

n = 74.

n = 80.

n = 80.
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For low‐risk potential deceased donors, 57/80 (71.3%) would test the donor for COVID‐19 with NP NAT; 20/78 (25.0%) with BAL NAT. For high‐risk donors, 44/80 (55.0%) reported that they would test the donor with BAL NAT.

### 3.4.2. Perceptions {#ajt15915-sec-0019}

It was difficult or extremely difficult for 28/83 (32.7%) of respondents to get inpatient COVID‐19 testing within 12 hours; 12/82 (14.6%) within 3 days; 4/81 (4.9%) within 7 days (Table [4](#ajt15915-tbl-0004){ref-type="table"}). Respondents reported more difficulty in obtaining outpatient COVID‐19 tests. It was difficult or extremely difficult for 51/81 (63.0%) of respondents to get outpatient COVID‐19 testing within 12 hours; 27/81 (33.3%) within 3 days; 14/78 (17.9%) within 7 days.

###### 

Perception of ease of arranging for COVID‐19 testing at respondents\' hospitals

                        Inpatient n (%)   Outpatient n (%)                                       
  --------------------- ----------------- ------------------ ----------- ----------- ----------- -----------
  Extremely easy        11 (13.3)         29 (35.4)          34 (42.0)   2 (2.5)     13 (16.0)   27 (34.6)
  Easy                  28 (33.7)         30 (36.6)          31 (38.3)   16 (19.8)   29 (35.8)   25 (32.1)
  Neutral               16 (19.3)         11 (13.4)          12 (14.8)   12 (14.8)   12 (14.8)   12 (15.4)
  Difficult             19 (22.9)         10 (12.2)          2 (2.5)     28 (34.6)   18 (22.2)   9 (11.5)
  Extremely difficult   9 (10.8)          2 (2.4)            2 (2.5)     23 (28.4)   9 (11.1)    5 (6.4)
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3.5. COVID‐19--SOT patient treatment {#ajt15915-sec-0020}
------------------------------------

Overall, 31/88 (35.2%) respondents reported caring for at least 1 COVID‐19--SOT patients. These respondents reported caring for 148 COVID‐19--SOT patients at the time this survey was administered (Table [5](#ajt15915-tbl-0005){ref-type="table"}; Figure [4](#ajt15915-fig-0004){ref-type="fig"}). Participants were asked to classify level of severity of illness: mild (no pneumonia) 80/148 (54.1%); moderate (pneumonia) 31/148 (20.9%); and critically ill 37/148 (25.0%). The majority of COVID‐19--SOT patients were KT recipients 103/148 (69.6%). Among the KT recipients, there was a substantial range in the distribution of time since transplant reported by respondents; 10/28 (35.7%) reported caring for KT patients with COVID‐19 within 1 year post‐KT; 14/28 (50.0%) 1‐5 years; 10/28 (35.7%) 6‐10 years; and 8/28 (28.6%) \>10 years. This was demonstrated by respondents who cared for LT and lung recipients as well.

###### 

Number of reported cases of COVID‐19 in SOT recipients categorized by severity of illness

+---------------------------------------------------------+-----------+-----------+----------+----------+-----------+
|                                                         | Kidney    | Liver     | Heart    | Lung     | Total     |
|                                                         |           |           |          |          |           |
|                                                         | n = 103   | n = 23    | n = 13   | n = 9    | n = 148   |
|                                                         |           |           |          |          |           |
|                                                         | n (%)     | n (%)     | n (%)    | n (%)    | n (%)     |
+=========================================================+===========+===========+==========+==========+===========+
| Mildly[^a^](#ajt15915-note-0012){ref-type="fn"} ill     | 58 (56.3) | 11 (47.8) | 8 (61.5) | 3 (33.3) | 80 (54.1) |
+---------------------------------------------------------+-----------+-----------+----------+----------+-----------+
| Moderately[^b^](#ajt15915-note-0013){ref-type="fn"} ill | 18 (17.5) | 6 (26.1)  | 5 (38.5) | 2 (22.2) | 31 (20.9) |
+---------------------------------------------------------+-----------+-----------+----------+----------+-----------+
| Critically ill                                          | 27 (26.2) | 6 (26.1)  | 0        | 4 (44.2) | 37 (25.0) |
+---------------------------------------------------------+-----------+-----------+----------+----------+-----------+

No pneumonia.

Pneumonia.
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![Respondent‐reported COVID‐19 cases by state‐level cumulative incidence. Cumulative incidence PMP on March 24, 2020](AJT-9999-na-g004){#ajt15915-fig-0004}

Irrespective of severity of illness, 25/32 (78.1%) of respondents reported having used hydroxychloroquine (HCQ) or chloroquine as off‐label therapy for COVID‐19; 15/32 (46.9%) reported having used azithromycin; 10/32 (31.3%) reported having used tocilizumab; 8/32 (25.0%) reported having used remdesivir (Table [6](#ajt15915-tbl-0006){ref-type="table"}). Pulse steroids were used by 2/32 (6.3%) of respondents, and ACEi/ARB were stopped by 2/32 (6.3%) of respondents. 36/60 (60%) of respondents reported being part of a remdesivir clinical trial; 12/19 (63.2%) respondents who were not participating in a remdesivir clinical trial reported having a compassionate use protocol. Other clinical trials were being participated in by 21/45 (46.7%) respondents; those included HCQ, tocilizumab, interferon lambda, clazakizumab, sarilumab, and convalescent plasma. Adverse effects of HCQ (arrhythmia) was reported by 2/27 (7.4%) of respondents. These therapies varied by type of SOT and severity of illness.

###### 

Number of respondents who reported using various pharmacologic therapies for COVID‐19--SOT patients categorized by degree of illness

+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
|                                                                                                 | Mild      | Moderate  | Critical  | Overall[^a^](#ajt15915-note-0015){ref-type="fn"} |
|                                                                                                 |           |           |           |                                                  |
|                                                                                                 | n = 19    | n = 19    | n = 18    | n = 32                                           |
|                                                                                                 |           |           |           |                                                  |
|                                                                                                 | n (%)     | n (%)     | n (%)     | n (%)                                            |
+=================================================================================================+===========+===========+===========+==================================================+
| Anti‐inflammatory                                                                               |           |           |           |                                                  |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Hydroxychloroquine[^b^](#ajt15915-note-0016){ref-type="fn"}                                     | 10 (52.6) | 16 (84.2) | 15 (83.3) | 25 (78.1)                                        |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Interferon alpha                                                                                | 0         | 0         | 0         | 0                                                |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Tocilizumab[^c^](#ajt15915-note-0017){ref-type="fn"}, [^a^](#ajt15915-note-0019){ref-type="fn"} | 0         | 1 (5.3)   | 9 (50.0)  | 10 (31.3)                                        |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Pulse steroids                                                                                  | 0         | 0         | 2 (11.1)  | 2 (6.3)                                          |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Antiviral                                                                                       |           |           |           |                                                  |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Remdesivir                                                                                      | 2 (10.5)  | 4 (21.1)  | 4 (22.2)  | 8 (25.0)                                         |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Oseltamivir/baloxavir                                                                           | 0         | 0         | 0         | 0                                                |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Lopinavir/ritonavir                                                                             | 1 (5.3)   | 0         | 3 (16.7)  | 4 (12.5)                                         |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Ribavirin                                                                                       | 0         | 0         | 0         | 0                                                |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Other agents                                                                                    |           |           |           |                                                  |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Azithromycin                                                                                    | 6 (31.6)  | 9 (47.4)  | 11 (61.1) | 15 (46.9)                                        |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Nitazoxanide                                                                                    | 0         | 0         | 0         | 0                                                |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Start ACEi/ARB                                                                                  | 0         | 0         | 0         | 0                                                |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+
| Stop ACEi/ARB                                                                                   | 0         | 2 (10.5)  | 1 (5.6)   | 2 (6.3)                                          |
+-------------------------------------------------------------------------------------------------+-----------+-----------+-----------+--------------------------------------------------+

Respondents could contribute to more than one column (mild, moderate, critical).

This represents the number of individual respondents who reported treating COVID‐19--SOT patients; if a respondent contributed to the mild and moderate columns, that respondent would only be counted once in the overall column.

Includes chloroquine.

Anti‐IL‐6.
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Immunosuppression modification varied by SOT type (Table [7](#ajt15915-tbl-0007){ref-type="table"}), and severity of illness. For KT recipients, antimetabolites were reported to have been stopped by 24/26 (92.3%) of respondents; calcineurin inhibitor (CNI) were reduced by 7/26 (26.9%) of respondents.

###### 

Number of respondents who reported changes in immunosuppression for COVID‐19--SOT patients

+----------------------------------------------------------------------------------------------------+-----------+----------+----------+----------+
|                                                                                                    | Kidney    | Liver    | Heart    | Lung     |
|                                                                                                    |           |          |          |          |
|                                                                                                    | n = 26    | n = 12   | n = 2    | n = 4    |
|                                                                                                    |           |          |          |          |
|                                                                                                    | n (%)     | n (%)    | n (%)    | n (%)    |
+====================================================================================================+===========+==========+==========+==========+
| Antimetabolite[^c^](#ajt15915-note-0017){ref-type="fn"}, [^a^](#ajt15915-note-0019){ref-type="fn"} |           |          |          |          |
+----------------------------------------------------------------------------------------------------+-----------+----------+----------+----------+
| Reduce                                                                                             | 5 (19.2)  | 2 (16.7) | 0        | 1 (25.0) |
+----------------------------------------------------------------------------------------------------+-----------+----------+----------+----------+
| Stop                                                                                               | 24 (92.3) | 8 (66.7) | 1 (50.0) | 1 (25.0) |
+----------------------------------------------------------------------------------------------------+-----------+----------+----------+----------+
| Calcineurin inhibitors[^b^](#ajt15915-note-0020){ref-type="fn"}                                    |           |          |          |          |
+----------------------------------------------------------------------------------------------------+-----------+----------+----------+----------+
| Reduce                                                                                             | 7 (26.9)  | 2 (16.7) | 1 (50.0) | 0        |
+----------------------------------------------------------------------------------------------------+-----------+----------+----------+----------+
| Stop                                                                                               | 4 (15.4)  | 1 (8.3)  | 0        | 1 (25.0) |
+----------------------------------------------------------------------------------------------------+-----------+----------+----------+----------+
| Steroids                                                                                           |           |          |          |          |
+----------------------------------------------------------------------------------------------------+-----------+----------+----------+----------+
| Reduce                                                                                             | 2 (7.7)   | 0        | 0        | 0        |
+----------------------------------------------------------------------------------------------------+-----------+----------+----------+----------+

Respondents could respond to more than one answer.

Includes mycophenolate mofetil (MMF).

Includes mTOR inhibitors.
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4. DISCUSSION {#ajt15915-sec-0021}
=============

In this national survey of transplant centers during the COVID‐19 pandemic, we found substantial reduction in transplant activity, wide variation in COVID‐19 testing practices, and use of off‐label or investigational therapies in the treatment of 148 COVID‐19--SOT recipients. Our survey results highlight the heterogeneity in practice patterns for COVID‐19 and the lack of treatment protocols.

Given the lack of uniform protocols, the variation in center‐specific practices is not surprising and likely driven by the anecdotal and reported experiences of transplant centers in other countries or hotspots within the United States, who have experience exponential increases in COVID‐19 hospital admissions and deaths.[^29^](#ajt15915-bib-0029){ref-type="ref"} High rates of transplant program cessation are likely reflective of uncertainty regarding the impact of COVID‐19 on SOT candidates and recipients and the potential for exponential case growth to overwhelm our current healthcare system.[^30^](#ajt15915-bib-0030){ref-type="ref"} This is supported by the large number of respondents who cited concern for inadequate PPE and hospital level resources. Additionally, without successful evidence‐based treatment paradigms or even consistent recipient and donor testing availability, uncertainty will likely continue to drive variation and reduction in transplant volume.

This is the first reported national survey of transplant center responses to COVID‐19. Strengths include a very high response rate of 79.3%, reflecting a strong national priority to better understand COVID‐19. Another strength is the capture of practice, policy, and perceptions early in the pandemic to identify where the needs are and where there was heterogeneity of practice.

Some limitations merit consideration. This survey mostly reflects KT and LT practice given the expertise of transplant leaders with these policies. Also, we were unable to obtain patient‐level data on COVID‐19 treatments or changes in IS regimens, thus any patient‐specific information was relayed through the survey respondent rather than through medical record evaluation.

In conclusion, this national survey of SOT programs suggests that COVID‐19 is widely recognized in the United States as a major threat to the field of SOT. However, there were no consistent policies, testing practices, or treatment mechanisms. Given the wide heterogeneity in center‐level response across the United States, ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence‐based practices.
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